Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?

被引:271
作者
Söderberg-Nauclér, C [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Dept Med, SE-17176 Stockholm, Sweden
关键词
autoimmune disease; cancer; cardiovascular disease; cytomegalovirus; immune evasion; inflammation;
D O I
10.1111/j.1365-2796.2006.01618.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Human cytomegalovirus (HCMV) is a herpes virus that infects and is carried by 70-100% of the world's population. During its evolution, this virus has developed mechanisms that allow it to survive in an immunocompetent host. For many years, HCMV was not considered to be a major human pathogen, as it appeared to cause only rare cases of HCMV inclusion disease in neonates. However, HCMV is poorly adapted for survival in the immunosuppressed host and has emerged as an important human pathogen in AIDS patients and in patients undergoing immunosuppressive therapy following organ or bone marrow transplantation. HCMV-mediated disease in such patients has highlighted the possible role of this virus in the development of other diseases, in particular inflammatory diseases such as vascular diseases, autoimmune diseases and, more recently, with certain forms of cancers. Current research is focused on determining whether HCMV plays a causative role in these diseases or is merely an epiphenomenon of inflammation. Inflammation plays a central role in the pathogenesis of HCMV. This virus has developed a number of mechanisms that enable it to hide from the cells of the immune system and, at the same time, reactivation of a latent infection requires immune activation. Numerous products of the HCMV genome are devoted to control central functions of the innate and adaptive immune responses. By influencing the regulation of various cellular processes including the cell cycle, apoptosis and migration as well as tumour invasiveness and angiogenesis, HCMV may participate in disease development. Thus, the various drugs now available for treatment of HCMV disease (e.g. ganciclovir, acyclovir and foscarnet), may also prove to be useful in the treatment of other, more widespread diseases.
引用
收藏
页码:219 / 246
页数:28
相关论文
共 289 条
[1]   Vascular thrombosis and acute cytomegalovirus infection in immunocompetent patients: Report of 2 cases and literature review [J].
Abgueguen, P ;
Delbos, V ;
Chennebault, JM ;
Payan, C ;
Pichard, E .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (11) :E134-E139
[2]   The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP [J].
Ahn, K ;
Gruhler, A ;
Galocha, B ;
Jones, TR ;
Wiertz, EJHJ ;
Ploegh, HL ;
Peterson, PA ;
Yang, Y ;
Fruh, K .
IMMUNITY, 1997, 6 (05) :613-621
[3]   Human cytomegalovirus inhibits antigen presentation by a sequential multistep process [J].
Ahn, KS ;
Angulo, A ;
Ghazal, P ;
Peterson, PA ;
Yang, Y ;
Fruh, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :10990-10995
[4]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[5]  
ALMEIDA GD, 1994, BLOOD, V83, P370
[6]   Potential relationship between herpes viruses and rheumatoid arthritis:: analysis with quantitative real time polymerase chain reaction [J].
Alvarez-Lafuente, R ;
Fernández-Gutiérrez, B ;
de Miguel, S ;
Jover, JA ;
Rollin, R ;
Loza, E ;
Clemente, D ;
Lamas, JR .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (09) :1357-1359
[7]  
Anderson JL, 2004, TEX HEART I J, V31, P33
[8]  
Asadullah K, 1999, BRIT J DERMATOL, V141, P94
[9]   Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcγ receptor homologs [J].
Atalay, R ;
Zimmermann, Z ;
Wagner, M ;
Borst, E ;
Benz, C ;
Messerle, M ;
Hengel, H .
JOURNAL OF VIROLOGY, 2002, 76 (17) :8596-8608
[10]   Infections and autoimmune diseases [J].
Bach, JF .
JOURNAL OF AUTOIMMUNITY, 2005, 25 :74-80